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SUMMARY
Tumor vasculature is derived from sprouting of local vessels (angiogenesis) and bone marrow (BM)-derived
circulating cells (vasculogenesis). By using a model system of transplanting tumors into an irradiated normal
tissue to prevent angiogenesis, we found that tumors were unable to grow in matrix metalloproteinase-9
(MMP-9) knockout mice, but tumor growth could be restored by transplantation of wild-type BM. Endothelial
progenitor cells did not contribute significantly to this process. Rather, CD11b-positivemyelomonocytic cells
from the transplantedBMwere responsible for tumor growth and the development of immature blood vessels
in MMP-9 knockout mice receiving wild-type BM. Our results suggest that MMP-9 could be an important
target for adjunct therapy to enhance the response of tumors to radiotherapy.INTRODUCTION
Tumor growth depends on the formation of new blood vessels
for the supply of oxygen and nutrients through processes known
as angiogenesis and vasculogenesis. Angiogenesis occurs
primarily by endothelial migration and sprouting from preexisting
blood vessels, while vasculogenesis involves the formation of
blood vessels in situ by recruitment of precursor cells such as
bone marrow (BM)-derived endothelial progenitor cells (EPCs)
from the circulation. Although the contribution of EPCs to vascu-
logenesis has been demonstrated in several models, including
hindlimb ischemia (Takahashi et al., 1999), vascular trauma
(Gill et al., 2001), and tumor growth (Lyden et al., 2001), the
extent to which EPCs are incorporated into newly formed blood
vessels in tumors varies significantly with the tumor model (De
Palma et al., 2003; Gothert et al., 2004; Lyden et al., 2001).
However, regardless of the different extent of the involvement
of EPCs, investigators have commonly observed BM-derived
vascular endothelial growth factor receptor-1 (VEGFR-1)-posi-
tive myelomonocytic cells associated with the tumor vasculature(De Palma et al., 2003; Lyden et al., 2001). Believed to be derived
from a common precursor cell known as the hemangioblast (Rafii
et al., 2002), myelomonocytic cells share many characteristics
with EPCs. Phenotypically, these cells share a number of surface
markers with EPCs, including platelet-endothelial cell adhesion
molecule-1 (PECAM-1; CD31), Tie-2, endoglin, and integrate
lectin and acetylated low-density lipoprotein (Fujiyama et al.,
2003; Rafii et al., 2002; Rohde et al., 2006). Functionally,
BM-derived myelomonocytic cells have been shown to mimic
EPCs in improving neovascularization in models of normal tissue
injury (Capoccia et al., 2006; Fujiyama et al., 2003; Moldovan
et al., 2000). These myelomonocytic cells are often observed in
the perivascular regions of the endothelium (De Palma et al.,
2003; Moldovan et al., 2000) or colocalized with endothelial cells
(Bailey et al., 2006; Capoccia et al., 2006; Ruzinova et al., 2003)
and have been shown to stabilize the tumor vasculature (Lyden
et al., 2001). Moreover, when these cells are depleted either
by using the Id1+/Id3/ mouse model, where mobilization of
VEGFR-1 and VEGFR-2 BMcells are genetically impaired (Lyden
et al., 2001), or by using a suicide gene therapy approach (DeSIGNIFICANCE
Tumors have an absolute requirement for neovasculature to grow beyond a very small size. This vasculature can arise by
proliferation and migration of nearby blood vessels (angiogenesis) or from colonization by circulating endothelial and other
cells primarily derived from the BM (vasculogenesis). Using transplantable tumor models in irradiated tissues (a model that
simulates tumors recurring after high-dose radiotherapy), we demonstrate that MMP-9, an enzyme involved in degrading
extracellular matrix, is required for vasculogenesis but not for angiogenesis. The BM-derived CD11b-positive myelomono-
cytic cells expressingMMP-9 are themajor contributors to tumor vasculogenesis. This study suggests that MMP-9 from the
BM-derived cells could be an important target for adjunct therapy to improve the therapeutic benefit for patients receiving
radiotherapy.
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MMP-9-Expressing CD11b Cells in Irradiated TumorsPalma et al., 2003), tumor growth is markedly inhibited. Overall,
these studies indicate that BM-derived myelomonocytic cells
play an important role in tumor vasculogenesis.
The BM-derived myelomonocytic cells that infiltrate tumors
and differentiate into macrophages are commonly referred to
as tumor-associated macrophages (TAMs). Clinical evidence
indicates that the presence of large numbers of TAMs correlates
with poor prognosis in cancers (Pollard, 2004). TAMs are a polar-
ized population of macrophages (Sica et al., 2006) and release
many angiogenic factors, including vascular endothelial growth
factor (VEGF), interleukin-8, tumor necrosis factor-a, and matrix
metalloproteinase-9 (MMP-9) (Dirkx et al., 2006; Lewis and
Pollard, 2006; Yang et al., 2004).
MMP-9 is a member of a family of zinc-containing endopepti-
dases that is involved in degradation of extracellular matrix
(ECM) and in vascular remodeling (Heissig et al., 2003). Like other
members of theMMPfamily,MMP-9 is synthesizedasan inactive
zymogen (pro-MMP-9) that is activated by proteolysis or autoly-
sis (Bergers andCoussens, 2000;Galis andKhatri, 2002).MMP-9
is involved in mobilizing EPCs and other progenitor cells from the
BMniche (Heissig et al., 2002), liberating growth factors including
VEGF (Bergers et al., 2000) and transforming growth factor-b
(Yu and Stamenkovic, 2000) from the matrix-bound forms, and
recruiting the BM-derived leukocytes to the tumor vasculature
(Jodele et al., 2005). MMP-9 provided by BM-derived cells has
been shown to initiate the angiogenic switch leading to tumor
growth and progression in K14-HPV16 epithelial squamous
carcinoma in mice (Coussens et al., 2000; Giraudo et al., 2004).
Radiotherapy is one of themost important treatmentmodalities
for cancer. However, many patients treated with radiotherapy
relapse in the irradiated field (Liang et al., 1991). It is unclear
how this occurs because, even though all of the tumor cells may
not be killed by radiation, it is unlikely that a sufficient number of
endothelial cells to allow for subsequent tumor growth could sur-
vive the largedosesdelivered in radiotherapy (Itasaka et al., 2007;
Tsai et al., 2005).Onepossibility to account for this is that a subset
of BM-derived cells could enter the irradiated tumor and restore
the vasculature by vasculogenesis. EPCs have recently been
shown to rescue tumor growth following treatment by vascular
disrupting agents (Shaked et al., 2006), but it remains to be deter-
mined whether this could also apply following irradiation.
In the present study we investigate the role of the BM-derived
CD11b-positive (CD11b+) myelomonocytic cells expressing
MMP-9 in the growth of tumors that are irradiated or trans-
planted into a tissue that has been irradiated prior to transplan-
tation. Tumors grown in previously irradiated tissues generally
show an increased latency period and a reduced growth rate
because of impaired neovascularization resulted from radia-
tion-induced injury to the host vasculature and connective tissue
(a phenomenon known as the ‘‘tumor bed effect’’) (Milas et al.,
1986). Such tumors also have an increased metastatic potential,
reduced blood perfusion and oxygen tension, and resistance to
treatments such as ionizing radiation and cytotoxic agents,
thereby mimicking human primary tumors that recur following
radiotherapy (Rofstad et al., 2005). We therefore hypothesized
that the vasculature of tumors grown in previously irradiated
tissues would derive from cells circulating in the blood stream
and in particular the BM. We show that tumors did not grow in
preirradiated subcutaneous tissues of MMP-9 knockout (KO)194 Cancer Cell 13, 193–205, March 2008 ª2008 Elsevier Inc.mice and that MMP-9 expressing CD11b+myelomonocytic cells
in the tumors from transplanted BM cells restored tumor growth
in these mice. We further provide evidence that MMP-9 express-
ing BM-derived myelomonocytic cells are essential to the
process of vasculogenesis and could be an important target
for adjunct therapy to high-dose radiotherapy.
RESULTS
BM-Derived Cells Infiltrating Tumors Are Not EPCs
We examined the BM-derived infiltrates in MT1A2 mouse
mammary carcinoma in FVB mice or radiation-induced fibrosar-
coma (RIF) in C3H mice by in situ hybridization for a Y-specific
DNA probe in female mice that had received syngeneic male
BM cells. Consistent with the fact that both the MT1A2 (Guy
et al., 1992) and RIF (see Experimental Procedures) tumors are
of female origin, we found no staining for the Y-probe in these
tumors grown in female mice (Figure 1A). However, when grown
in female mice transplanted with male BM, we saw significant
infiltration of male-derived cells that was different for the two
tumors: MT1A2 tumors showed BM-derived infiltrates mainly in
perivascular regions, whereas RIF tumors showed a more
diffusely distributed pattern (Figure 1A).
Because the dose of irradiation (IR) used in this study (20 Gy)
would be expected to sterilize essentially all of the endothelial
cells in the irradiated tissue prior to tumor transplantation and
hence abrogate local angiogenesis (Udagawa et al., 2007), we
hypothesized that the BM-derived infiltrates may be EPCs and
that the tumors grown in the irradiated bed might incorporate
more EPCs from the BM to establish the tumor vessels by vascu-
logenesis. First, we examined whether 20 Gy of IR to subcutane-
ous tissues of the lower back of the mice would cause ulceration
to the skin.We found that there was no difference in the histology
of the skin between irradiated and nonirradiated mice
(Figure S1A available online) and that there were infiltrating cells
present only when the tumor was implanted on the irradiated
skin (Figure S1B). We therefore quantified the BM-derived
EPCs in MT1A2 tumors grown in the preirradiated tissues
(‘‘pre-IR bed’’) of mice that had received BM cells from Tie2lacZ
transgenic mice, which express the lacZ reporter gene driven
by the endothelial receptor tyrosine kinase promoter Tie2
(Schlaeger et al., 1997). EPCs were detected by double-label
immunostaining for X-gal and CD31. The growth kinetics
showed that tumors grew significantly slower in preirradiated tis-
sues (Figure 1B and Figure S3), as reported by others (Milas
et al., 1986; Rofstad et al., 2005). We confirmed that Tie2 marks
endothelial cells in MT1A2 tumors by growing the tumors in Tie2-
lacZ transgenic mice (Figure 1C). However, when grown in mice
that had received BM cells from Tie2lacZ mice, the tumors
showed only rare incorporation of EPCs in the vessels
(Figure 1C). Tumors grown in preirradiated tissues of these BM
transplanted mice also showed very low levels of EPCs in the
tumor vasculature (Figure 1C), and the proportion of CD31 and
X-gal double-positive tumor vessels did not differ significantly
between control tumors without IR and tumors grown in preirra-
diated tissues (Figure 1C). However, in the tumors grown in
preirradiated tissues we observed a significant number of
Tie2-expressing cells in stromal regions of the tumors that
were not positive for CD31 staining (Figure 1D).
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Minimally to Tumor Vasculogenesis
(A) MT1A2 and RIF tumors grown in female mice
(upper panel) or in female mice that had received
syngeneic male BMcells (lower panel). The tumors
were stained for CD31 (brown) and Y-DNA probe
by in situ hybridization (dark blue). Arrowheads
(black) in the lower panel indicate cells positively
stained for the Y-probe.
(B) Growth kinetics of MT1A2 tumors grown in
nonirradiated (control; open symbols) or preirradi-
ated (pre-IR bed; filled symbols) subcutaneous
tissues of FVB mice.
(C) MT1A2 tumors grown in Tie2lacZ transgenic
mice (Tie2lacZ mice) or in FVB mice that had
received BM cells from Tie2lacZmice (FVB + Tie2-
lacZ BM). Tumors in FVB + Tie2lacZ BM were
grown in nonirradiated (control) or preirradiated
(pre-IR bed) tissues. Vessels were stained with
CD31 (brown) and X-gal (blue). Arrowheads (black)
indicate some of the BM-derived LacZ-positive
cells. The graph shows quantification of CD31-
and X-gal-double-positive vessels cells as a
percentage of the total CD31-positive cells in
high power field (HPF). The difference between
control and pre-IR bed was not statistically signif-
icant (p > 0.05).
(D) A significant number of X-gal (blue)-positive but
CD31 (brown)-negative cells were observed in the
tumors grown in the preirradiated tissues (pre-IR
bed) of FVB + Tie2lacZ BM (indicated with black
arrowheads). Quantification of X-gal-positive but
CD31-negative cells counted per HPF is shown
on the right. The data were not, however, signifi-
cantly different between control and pre-IR bed
(p > 0.05).
Symbols and error bars in (B), (C), and (D) are the
mean ± SEM for nR 5 mice per group.To determine if the minimal incorporation of BM-derived EPCs
in the tumors was a general phenomenon, we examined a
number of different tumor models: TG1-1 mouse mammary
carcinoma or 6780 lymphoma in FVB mice with BM cells from
Tie2lacZ mice; and the Lewis lung carcinoma (LLC) or B16F1
melanoma in C57Bl/6 with BM cells from either Tie2GFP or
Rosa26 transgenic mice. Double-label immunostaining for
BM-derived EPCs again showed that there was only rare incor-
poration of EPCs in the tumor vasculature of all control tumors
and tumors grown in preirradiated tissues (Figure S2).
Overall, the results suggest that BM-derived EPCs contribute
only to a small extent to tumor blood vessels and that they are
not a major component of the BM-derived infiltrates in the
tumors used in this study.
CD11b+ Myelomonocytic Cells Account for Most
of the BM-Derived Infiltrates in the Tumors
and Are Increased by IR
To ascertain the nature of theBM-derived infiltrates in the tumors,
we examined MT1A2 tumors grown in preirradiated tissues of
mice that had received BM cells frommice ubiquitously express-
ing green fluorescent protein (GFP). The GFP-expressing BM-
derived infiltrates in the tumors were examined for markers ofinflammatorycells includingcytotoxicTcells (CD8a),helperTcells
(CD4), natural killer cells (CD49b), monocytes/macrophages
(CD11b), dendritic cells (CD11c), and granulocytes/neutrophils
(Gr-1). Double-label immunofluorescent staining showed that
a significant number of GFP-expressing cells colocalized with
CD11b (Figure 2A). Although there were some CD4- or CD8a-
positive cells detected in the tumors, they did not colocalize with
GFP (Figure2A), indicating that thesecellsarenotderived fromthe
BM but possibly from the thymus or spleen. We did not observe
any detectable numbers of CD11c-, Gr-1-, or CD49b-positive
cells in the tumors that were also positive for GFP (Figure 2A).
We next determined how the BM-derived CD11b+ myelomo-
nocytic cells in the tumors were affected by IR. Tumors were
grown either without IR (control) or in preirradiated tissues
(pre-IR bed) as previously. We also tested a clinically relevant
IR model by delivering a single dose of IR (20 Gy) to already
established tumors at approximately 200 mm3 and allowing the
tumors to regrow beyond the volume at which they were irradi-
ated (IR tumor). Immunostaining showed that both IR tumors
and tumors grown in preirradiated tissues had significantly
more CD11b+ cells compared to control MT1A2 tumors of the
same size (Figures 2B and 2C). In RIF tumors, we also observed
more CD11b+ cells in the IR tumors, although tumors grown inCancer Cell 13, 193–205, March 2008 ª2008 Elsevier Inc. 195
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controls (Figures 2B and 2C). The latter was because there were
only small proportions of viable cells present in RIF tumors grown
in preirradiated tissues.
CD11b+ Myelomonocytic Cells Express MMP-9
Because of the known role of monocytes/macrophages in
promoting tumor angiogenesis (Coussens et al., 2000; Giraudo
Figure 2. BM-Derived CD11b+ Myelomonocytic Cells Are Recruited
to the Tumors with IR
(A) Immunostaining of MT1A2 tumors grown in the preirradiated tissues of FVB
mice that had received BM cells from mice ubiquitously expressing GFP.
Tumor sections were stained for CD4 (red), CD8a (red), CD49b (red), CD11c
(red), CD11b (red), or Gr-1 (red), and anti-GFP (green), counterstained with
DAPI (blue). Colocalization of red, green, and blue is shown in white. Insets
in the middle panels show magnified regions of the microphotograph where
indicated with asterisks.
(B) Immunostaining for CD11b (red) in tumors with no IR (control), irradiated
tumors (IR tumor), or tumors grown in the irradiated bed (pre-IR bed) for
MT1A2 (upper panel) and RIF (lower panel). Nucleus staining with DAPI is
shown in blue.
(C) Quantification of CD11b+ myelomonocytic cells in (B) for MT1A2 (left) and
RIF (right) tumors. Symbols and error bars represent themean ± SEM for nR 4
animals per group. *p < 0.05, **p < 0.01, and ***p < 0.001, respectively,
determined by one-way ANOVA.196 Cancer Cell 13, 193–205, March 2008 ª2008 Elsevier Inc.et al., 2004; Lin et al., 2006) we hypothesized that CD11b+ mye-
lomonocytic cells contribute to the vasculogenesis of the tumors
grown in the irradiated bed by remodeling the ECM. We tested
this hypothesis by examining the expression of MMP-9, one of
the key players in remodeling ECM, in CD11b+ cells using
double-label immunofluorescent staining. Histological examina-
tion showed that most of the CD11b+ cells were also MMP-9
positive in MT1A2 tumors (Figure 3A). Moreover, irradiated
tumors (IR tumors) and tumors grown in the irradiated bed
(pre-IR bed) showed an increase in MMP-9-positive areas and
Figure 3. CD11b+ Myelomonocytic Cells Express MMP-9 in the
Tumors
(A) Double-label immunofluorescent staining for CD11b (red) and MMP-9
(green) in MT1A2 (upper panel) and RIF (lower panel) tumors with no IR
(control), irradiated tumors (IR tumor), or grown in preirradiated tissues
(pre-IR bed). Colocalization of CD11b and MMP-9 is shown in white with
DAPI counterstaining.
(B) Quantification of MMP-9-positive area determined by the point-count
method (left) and the number of CD11b- and MMP-9-double-positive cells in
nonnecrotic regions (right) of MT1A2 tumors.
(C) RIF tumors as in (B). Symbols and error bars in (B) and (C) are mean ± SEM
for n R 4 animals per group. *p < 0.05, **p < 0.01, and ***p < 0.001, respec-
tively, by one-way ANOVA.
(D) Western blot for MMP-9 in MT1A2 (left panel) and RIF (right panel) tumors.
GAPDH was used as the loading control.
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Tumor Growth in Preirradiated Tissues of
MMP-9 KO Mice
(A) MT1A2 tumor growth in preirradiated tissues of
WT mice that had received the BM cells from WT
mice (WT + WT BM), MMP-9 KO mice receiving
BM cells from MMP-9 KO mice (KO + KO BM),
MMP-9 KO mice receiving BM cells from WT
mice (KO +WT BM), or WT mice that had received
the BM cells fromMMP-9 KOmice (WT + KO BM).
Note that tumor growth was severely impaired in
KO + KO BM and was restored in KO + WT BM.
(B) Zymography was used to determine the
efficiency of the BM reconstitution. Whole BM
cells of the recipients were isolated and analyzed
for MMP-9 activity at R4 weeks post-BM trans-
plantation. Each lane represents one mouse.
(C) Quantification of CD11b+ myelomonocytic
cells in HPF from tumors in (A).
(D) Immunostaining of the tumors from KO + KO
BM for CD11b myelomonocytic cells (red) and
MMP-9 (green), counterstained with DAPI (blue).
(E) Immunostaining of the tumors from KO + WT
BM as in (D).
(F) Quantification of MMP-9- and CD11b-double-
positive cells in tumors from KO + KO BM or
KO+ WT BM.
Symbols in (A), (C), and (F) are the mean ± SEM for
nR 5 mice per group.in the numbers of CD11b- and MMP-9-double-positive cells
(Figure 3B).
In RIF tumors, we similarly observed an increase in MMP-
9-positive areas in ‘‘IR tumors’’ and ‘‘pre-IR bed,’’ and increased
numbers of CD11b- and MMP-9-positive cells in ‘‘IR tumors’’
(Figure 3C). However, we also observed numerous CD11b-
negative tumor cells that strongly expressed MMP-9 (Figure 3A
and Figure S4A), suggesting that RIF tumor cells themselves
are a significant source of MMP-9.
To confirm the histological observations of MMP-9 expres-
sion, we performed immunoblots with tumor lysates. We found
that IR, either of the tumors directly (‘‘IR tumors’’) or of the
transplantation site (‘‘pre-IR bed’’), increased the expression of
MMP-9 in both the MT1A2 and RIF tumors (Figure 3D), consis-
tent with the histological observations. The higher expression
of MMP-9 in RIF tumors especially from ‘‘pre-IR bed’’ compared
to that in MT1A2 tumors is likely due to the strong expression of
MMP-9 by the RIF tumor cells.
Genetic Depletion of MMP-9 Abrogates Tumor
Vasculogenesis
To address the role of MMP-9 in vasculogenesis, we used
MMP-9 knockout (KO) mice with tumors grown in preirradiated
tissues to inhibit angiogenesis. We selected MT1A2 tumors
over RIF tumors because MT1A2 tumors are syngeneic to
MMP-9 KO and wild-type (WT) mice, and the source of MMP-9
in the tumors is largely restricted to CD11b+ myelomonocytic
cells, allowing us to investigate the role of the BM-derivedCD11b+ myelomonocytic cells in vasculogenesis. We first
examined the growth of MT1A2 tumors in MMP-9 KO and WT
mice and found that the tumors grew progressively in the
MMP-9 KO mice, albeit a little slower than in the WT mice
(Figure S5A). However, tumor growth in preirradiated tissues
was severely impaired in MMP-9 KO mice (Figure S5B) or in
MMP-9 KO mice that had received BM cells from MMP-9 KO
mice (MMP-9 KO mice + KO BM) (Figure 4A) compared to their
WT counterparts (Figure S5B and Figure 4A).
We next determined whether functional BM could restore
tumor growth in preirradiated tissues of MMP-9 KO mice by
transplanting BM cells from WT mice into MMP-9 KO mice
(MMP-9 KO mice + WT BM). The efficiency of BM reconstitution
was confirmed by zymography at the time of tumor implantation
(R4 weeks post-BM transplantation), which showed that the
activity of MMP-9 in the BM could be restored in MMP-9 KO
mice or lost in WT mice by transplanting BM cells (Figure 4B).
Reconstitution of the BM in MMP-9 KO mice with WT BM
completely restored the growth of the tumors in the preirradiated
site to that of WT mice (Figure 4A). However, WT mice receiving
BM cells from MMP-9 KO mice (WT mice + KO BM) showed no
difference in tumor growth in preirradiated tissues compared to
WT mice + WT BM (Figure 4A), indicating that non-BM-derived
cells can compensate for the lack of MMP-9 in BM cells. We
examined CD11b+ myelomonocytic cells in the tumors of all
four groups and found that there was no significant difference
in the number of CD11b+ cells in the tumors from the different
groups (Figure 4C). When examined for MMP-9 in tumors grownCancer Cell 13, 193–205, March 2008 ª2008 Elsevier Inc. 197
Cancer Cell
MMP-9-Expressing CD11b Cells in Irradiated Tumors198 Cancer Cell 13, 193–205, March 2008 ª2008 Elsevier Inc.Figure 5. Immature Vessels Are Developed
in MMP-9 KO Mice + WT BM to Support
Tumor Growth in Preirradiated Tissues
(A) Immunostaining of CD31 (red) and a-SMA
(green) in MT1A2 tumors grown in the wild-type
(WT) or MMP-9 KO (KO) mice.
(B) Number of CD31-positive vessels per HPF (left)
and proportions of CD31-positive vessels associ-
ated with a-SMA (right) in tumors from (A).
(C) Immunostaining of CD31 (red) and a-SMA
(green) for tumors from Figure 4A. Group names
are as in Figure 4A.
(D) Quantification of CD31-positive vessels per
HPF (upper panel) and proportions of CD31-posi-
tive vessels associated with a-SMA (lower panel)
in the tumors from (C). Symbols in (B) and (D) are
the mean ± SEM for n R 5 animals per group.
*p < 0.05, **p < 0.01, and ***p < 0.001, respectively,
determined by one-way ANOVA.
(E) Functional blood vessels of tumors grown in
preirradiated tissues of WT, KO, or KO + WT BM
examined by intravenous infusion with Hoechst
33342 (blue). Tumor sections were stained with
CD31 (red).in preirradiated tissues of MMP-9 KO mice + WT BM, we found
that the majority of MMP-9-positive cells (91% ± 3%) were
positive for CD11b (Figures 4E and 4F), while there were no
MMP-9-positive CD11b myelomonocytic cells in those tumors
fromMMP-9KOmice + KOBM (Figures 4D and 4F) as expected,
or fromWTmice+KOBM(Figure 6D). In the tumors fromWTmice
+ KO BM, someMMP-9-positive areas were observed with mor-
phology of smooth muscle- or fibroblast-like cells (Figure S5C).
Overall, the results suggest that CD11b+ myelomonocytic cells
are the main source of MMP-9 and that these cells can restore
tumor growth in irradiated tissues ofMMP-9 KO mice.
To determine whether the restored tumor growth by functional
BMwas associated with vasculogenesis, we first tested a possi-
bility that CD11b+ myelomonocytic cells differentiate into endo-
thelial cells in tumors. By immunostaining, we observed in
tumors of all four groups that CD11b+ cells did not colocalize
with CD31 (Figure S5E), suggesting that CD11b+ myelomono-
cytic cells did not differentiate to the tumor endothelium. This
also indicates that CD11b+myelomonocytic cells indirectly con-
tributed to vasculogenesis. We examined vessel density and
maturity in the tumors, determined by the number of CD31-pos-
itive vessels and the proportion of CD31-labeled endothelial cellssurrounded by pericytes, identified by
a-smooth muscle actin (a-SMA) immu-
nostaining. Without IR, most of the
vessels in tumors grown in WT (87% ±
2%) or MMP-9 KO (87% ± 2%) mice
were associated with a-SMA (Figures
5A and 5B). In sharp contrast, the vascu-
lature of the tumor growing in the preirra-
diated site of WT + WT BM was sparsely
covered by a-SMA (Figure 5C). This is
consistent with our hypothesis of a differ-
ent etiology of the vessels in the two situ-ations: in the unirradiated tissue most of
the vessels arise from angiogenesis (local sprouting), whereas
in preirradiated bed they can only arise from vasculogenesis
(circulating cells). On the other hand, the majority of the vessels
in the very small (and nongrowing) tumors in the irradiated site
ofMMP-9 KO mice + KO BM had a mature appearance with ex-
tensive a-SMA coverage (Figure 5C). Moreover, while there was
little or no difference in the density and maturity of the CD31-
positive endothelial cells between the WT and MMP-9 KO mice
without IR (Figure 5B), the vessel density was significantly lower
in the very small nongrowing tumors growing in the irradiated site
of the MMP-9 KO mice, and this was restored to WT levels by
transplantation of WT BM cells (Figure 5D).
We further examined whether the impaired tumor growth in
preirradiated tissues of MMP-9 KO mice was due to an impair-
ment in the function of the tumor vessels. To investigate this
we intravenously injected Hoechst 33342 into WT mice, MMP-
9KOmice, orMMP-9KOmice +WTBM, all of which had tumors
implanted in preirradiated tissues. We found that the vessels
were well-perfused in the tumors grown in preirradiated tissues
ofMMP-9 KO mice and that there was no difference in function-
ality of vessels in the tumors betweenWTmice,MMP-9KOmice,
or MMP-9 KO mice + WT BM (Figure 5E).
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MMP-9 in CD11b+ Myelomonocytic Cells
by ZA Inhibits Tumor Growth in the Preirra-
diated Site
(A) MT1A2 tumor growth with (ZA, n = 5) or without
(control, n = 4) ZA in preirradiated tissues of
MMP-9 KO mice that had received BM cells from
WT mice.
(B) MT1A2 tumor growth in preirradiated tissues of
WTmice receiving BM cells fromMMP-9KOmice.
n = 5 animals per group. Symbols and error bars
in (A) and (B) are the mean ± SEM.
(C) Immunostaining of the tumors from (A) for
MMP-9 (green), CD11b (red), and nuclei (blue).
(D) Immunostaining of the tumors from (B) as in (C).
(E) Quantification of CD11b+ cells (upper left),
percentage of MMP-9-expressing CD11b+ cells
(upper right), CD31-positive endothelial cells
(lower left), and CD31-positive vessels that were
associated with a-SMA (lower right) in the tumors
from (A).
(F) Quantification of the parameters as in (E) but
from tumors in (B).
Error bars in (E) and (F) are SEM. **p < 0.01 and
***p < 0.001, respectively, determined by two-
tailed Student’s t test.
onate zolendronic acid (ZA, Zometa),
a clinically available agent to ameliorate
bone metastases that was recently
reported to selectively target MMP-9
expressing macrophages in K14-HPV16
cervical carcinoma in mice (Giraudo
et al., 2004). MT1A2 tumors were grown
in the preirradiated tissues in MMP-9 KO
mice that had received BM cells from WT
mice (MMP-9KOmice+WTBM) asprevi-
ously described. Hence tumors grown in
these mice, the major source of MMP-9,
would come from the BM-derived
Taken together, these data suggest that the failure of the
tumors to grow in the preirradiated site of MMP-9 KO mice
was the result of abrogation of both angiogenesis (by irradiation)
and of vasculogenesis (by lack of MMP-9 in BM-derived cells),
and that the blood vessels within the tumors (Figure 5) and
around the periphery (Figure S5D) of the small tumors in the pre-
irradiated tissue of MMP-9 KO mice were mature and well-per-
fused normal vessels, probably co-opted by growth of the tumor
into surrounding normal tissue. Overall, it suggests that restora-
tion of tumor growth in the irradiated tissue by WT BM allowed
immature vessels to form byMMP-9 expressing CD11b+myelo-
monocytic cells that arose from the transplanted BM.
Pharmacological Inhibition of CD11b+ Myelomonocytic
Cells Expressing MMP-9 Significantly Reduces Tumor
Growth in Preirradiated Tissues
Based on the above results, we hypothesized that selective
inhibition of CD11b+ myelomonocytic cells expressing MMP-9
would inhibit BM-derived vasculogenesis and tumor growth in
preirradiated tissues. To test this, we used the aminobisphosph-
CD11b+myelomonocytic cells. In order to determine the specific
activity of ZA in targeting MMP-9 from BM-derived cells but not
from other tissues, we also tested ZA in WT mice receiving BM
cells from MMP-9 KO mice (WT mice + KO BM). Because WT
mice + KO BM do not have MMP-9 expressing CD11b+ myelo-
monocytic cells, the tumorgrowth inpreirradiated tissuesof these
mice should not be affected by the ZA treatment. Treatment with
ZA at 100 mg/kg intraperitoneally once per day for up to 6 weeks
produced a significant inhibition of tumor growth in the irradiated
site of MMP-9 KO mice + WT BM (Figure 6A). In contrast, there
was no effect of ZA on tumor growth of WT mice + KO BM
(Figure 6B), as predicted. Histological examinations showed
that ZA-treated tumors inMMP-9 KO mice + WT BM had similar
numbers of CD11b+ myelomonocytic cells but a smaller fraction
that were MMP-9 positive (Figures 6C and 6E). In addition, ZA-
treated tumors showedsignificantly fewer numbersofCD31-pos-
itive vessels than the control tumors (Figure 6E). When examined
for vesselmaturity, ZA-treated tumors had significantlymore ves-
sels associatedwitha-SMA than the control tumors (Figure 6E), in
agreement with the data obtainedwithMMP-9KOmice + KOBM
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ExpressingMMP-9 byDTFurther Abrogates
Tumor Growth in Preirradiated Tissues of
MMP-9 KO + DTR BM
(A) Peripheral blood of MMP-9 KO mice that
had received BM cells from transgenic mice
expressing diphtheria toxin receptor (DTR) and
GFP driven by CD11b promoter (DTR BM) or of
WT mice without BM transplantation (WT). These
mice were treated with or without diphtheria
toxin (DT, 10 ng/g). Blood was analyzed for GFP
fluorescent intensity as an indicator of CD11b
levels at 24 hr posttreatment. Note that treat-
ment with DT 10 ng/g in DTR BM mice resulted
in GFP signal similar to that in WT mice with or
without DT.
(B) Peripheral blood ofMMP-9 KOmice + DTR BM
(DTR BM) treated without DT (-DT), with 10 ng/g
DT, 5 ng/g DT, or 2 mg/g carrageenan (Car) at
24 hr posttreatment. Blood of WT mice (WT) with
andwithout DT 10 ng/g is also shown. R, red blood
cells; L, lymphocytes; G, granulocytes; M,
monocytes.
(C) Quantification of monocytes gated in red from
(B). Symbols and error bars indicate the mean ±
SEM for n R 5 mice per group. ***p < 0.001
analyzed by one-way ANOVA.
(D) MT1A2 tumor growth in preirradiated tissues of
MMP-9 KO mice + DTR BM (DTR BM) without DT
(DT, n = 4), with DT (5 ng/g, n = 5), or with Car
(n = 4). Tumors were also grown in preirradiated
tissues of WT mice receiving BM cells from WT
mice (WT BM, n = 5) or MMP-9 KO mice (MMP-9
KO, n = 5) that were treated with DT (5 ng/g). Error
bars indicate SEM.(Figure 5). In WTmice + KO BM, we did not observe any CD11b+
myelomonocytic cells that were MMP-9 positive (Figure 6D), and
there was no significant difference in the number of CD11b+ cells
between ZA-treated and control tumors (Figure 6F). As found
earlier, the percentage of CD31-positive tumor vessels and those
associatedwitha-SMAwas low in theWTmice+KOBM, and this
was not affected by ZA (Figure 6F). In summary, ZA efficiently
targeted MMP-9 expressed in the BM-derived CD11b+ myelo-
monocytic cells in the tumor, inhibited the growth of tumors in
the preirradiated tissues, and reduced the numbers of immature
(tumor-like) vessels in the tumors.
Conditional Ablation of CD11b+ Myelomonocytic Cells
Further Abrogates Tumor Growth in Preirradiated
Tissues of MMP-9 KO Mice + Functional BM Cells
We further examined the role of CD11b+myelomonocytic cells in
restoring tumor growth in preirradiated tissues by conditionally
ablating CD11b+ cells. To do this, we transplanted BM cells
from transgenic mice expressing human diphtheria toxin recep-
tor (DTR) and GFP driven by the CD11b promoter (Stoneman
et al., 2007) into lethally irradiated MMP-9 KO mice (MMP-9
KOmice + DTR BM). Treatment by diphtheria toxin (DT, 10 ng/g)
ofMMP-9 KOmice + DTR BM effectively depleted GFP-positive
CD11b+ cells in the peripheral blood at 24 hr postadministration
(Figure 7). In contrast, administration of DT in WT mice showed
no depletion of CD11b+ myelomonocytic cells (Figures 7A and
7B). However, repeated administration of DT 10 ng/g once in
every 2 days inMMP-9 KO mice + DTR BM resulted in mortality
in 20 days (Figure S6A). We therefore lowered the dose of DT to
5 ng/g once every 2 days and still observed effective depletion of
CD11b+ myelomonocytic populations in the peripheral blood of
MMP-9 KO mice + DTR BM (Figures 7B and 7C). The depleted
CD11b+ cells rebounded to untreated levels at 48 hr (data not
shown). We also tested another approach to deplete CD11b+
cells by using carrageenan, a compound that eliminates macro-
phages (Li et al., 2007). Although carrageenan at 2 mg/mouse
showed effective depletion of CD11b+ myelomonocytic cells at
24 hr (Figures 7B and 7C), it also resulted in a significant expan-
sion of granulocyte populations (Figure 7B). Moreover, carra-
geenan-treated mice showed significant bodyweight loss and
some early mortality (Figures S6A and S6B). The dose of carra-
geenan was therefore lowered to 1 mg/mouse, but once per
week treatment was ineffective in maintaining low levels of
CD11b+ myelomonocytic cells (data not shown).
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mice, tumor growth was significantly inhibited in MMP-9 KO
mice + DTR BM receiving DT (5 ng/g), mimicking the lack of
tumor growth in MMP-9 KO mice (Figure 7D). Treatment with
DT in WT mice + WT BM showed no effect in tumor growth
(Figure S6E). Carrageenan, on the other hand, did not inhibit
tumor growth (Figure 7D), likely due to the rebound of CD11b+
myelomonocytic cells resulting from the once a week treatment
regimen. Overall, these results further demonstrate that MMP-9
expressing CD11b+ myelomonocytic cells play an essential role
in promoting tumor growth in preirradiated tissues.
DISCUSSION
In this study, we show the crucial role played by the ECM
degrading enzyme MMP-9 provided by BM-derived CD11b+
myelomonocytic cells in allowing tumors to grow in irradiated
normal tissues of the mice. We used the irradiated tumor bed
model to abrogate local angiogenesis so as to examine the
role of BM-derived cells in tumor growth. We demonstrate that
CD11b+ myelomonocytic cells are recruited into irradiated
tumors and into tumors growing in preirradiated tissues, and
these cells restored tumor growth inMMP-9KOmice by allowing
immature blood vessels to develop. Further, when MMP-9 or
a major source of MMP-9-expressing cells are genetically
absent, ablated, or chemically inhibited, tumors in preirradiated
tissues fail to grow beyond a very small size and are composed
of normal, mature blood vessels.
Given the role of MMP-9 in degrading and remodeling the
ECM, CD11b+ myelomonocytic cells expressing MMP-9 are
likely to be important in reorganizing stromal compartments of
tumors. In particular, by degrading the ECM they could provide
a means for endothelial cells to enter or migrate to the tumor
when the existing endothelial cells in and adjacent to the tumor
cannot proliferate because of the local irradiation they have
received. MMP-9 is involved in cleaving fibrillar type I collagen,
the major constituent of the extracellular matrix to which endo-
thelial cells are exposed in an injured tissue, allowing growth
factor-induced angiogenesis to occur (Seandel et al., 2001).
Moreover, MMP-9 provided by BM-derived macrophages has
been shown to be essential in capillary branching in ischemia-
induced revascularization of normal tissues (Johnson et al.,
2004). MMP-9 may also enhance local angiogenesis in a spatio-
temporal manner due to its ability to cleave membrane-bound
VEGF, thereby increasing bioavailable levels of VEGF (Bergers
et al., 2000), a growth factor that is critical for survival and growth
of endothelial cells (Ferrara et al., 2003). Macrophages them-
selves can also express VEGF, and these cells are observed in
poorly vascularized areas of human breast carcinoma (Lewis
et al., 2000). Other functions of macrophages, such as inducible
nitric oxide synthase, arginase, and cyclooxygenase-2, have
been reported to be important in growth of irradiated tumors in
mice (Tsai et al., 2007).
CD11b+ myelomonocytic cells, including a subset of
CD11b+Gr-1+ myeloid suppressor cells, are increasingly recog-
nized for their roles in promoting tumor progression. Studies
have shown that these cells enhance tumor angiogenesis
(Yang et al., 2004), prepare the premetastatic niche in the lung
(Hiratsuka et al., 2006), and are responsible for the refractorinessof tumors to anti-VEGF treatment (Shojaei et al., 2007). Our study
is consistent with these reports by showing that they promote
tumor growth in preirradiated tissues of mice when local angio-
genesis is inhibited.
Increased leukocyte infiltration, especially by CD68-positive
macrophages, is observed in biopsy samples of rectal cancer
patients after high-dose (and short-term) and low-dose (and
long-term) fractionated radiotherapy (Baeten et al., 2006). The
authors of this study proposed that an increased expression of
adhesion molecules such as intracellular adhesion molecule-1,
vascular cell adhesion molecule, and E-selectin on tumor
endothelium after radiotherapy is responsible for stimulating
leukocyte infiltration in the tumors. However, other factors,
including VEGF and stromal-cell derived factor-1 (SDF-1), have
been also reported to be essential in recruiting BM-derived
myelomonocytic cells to tumors (Grunewald et al., 2006; Petit
et al., 2007). VEGF and SDF-1 are downstream targets of
hypoxia-inducible factor-1 (HIF-1), a transcription factor induced
by hypoxia due to stabilization under hypoxic conditions
(Ceradini et al., 2004; Semenza, 2003). HIF-1 levels are likely to
increase in tumors regrowing after irradiation or tumors grown
in preirradiated tissues due to the increased levels of hypoxia
(Kim et al., 1993; Teicher et al., 1994). Furthermore, recent stud-
ies have shown that irradiation increases HIF-1 activity in tumors
(Moeller et al., 2004), and this occurs by recruited macrophages
in irradiated tumors producing nitric oxide, which in turn nitrosy-
lates cysteine residues of the oxygen-dependent degradation
domain of HIF-1a, thereby stabilizing it (Li et al., 2007).
Overall, there is strong evidence that BM-derivedmyelomono-
cytic cells promote tumor growth and that they do so by forming
a positive feedback loop with many other components of the
tumor microenvironment. Indeed, several investigators have
reported that targeting TAMs produces significant antitumor
activity (Allavena et al., 2005; Lin et al., 2001; Luo et al., 2006;
Zeisberger et al., 2006). However, it is evident that tumors
show large variations in recruiting and utilizing these BM-derived
cells, and our study demonstrates that the pattern of BM-derived
infiltrates and reliance for the source of MMP-9 varies widely
betweenRIF andMT1A2 tumors. Hence, prospective knowledge
of tumor cytokines and their role in the recruitment of BM-
derived cells will be important to derive maximum antitumor
activity from therapies targeting these cells.
We observed a minimal contribution of BM-derived EPCs to
the vasculature of tumors grown in preirradiated tissues. This
raises the question as to the source of the additional endothelial
cells. Studies have shown that there aremature circulating endo-
thelial cells derived from vessel wall turnover and that these cells
are increased in patients with some types of cancer (Bertolini
et al., 2006). Recently, Aicher and colleagues reported that there
are non-BM-derived circulating progenitor cells from organs
such as the small intestine and liver and that these cells incorpo-
rate into sites of neovascularization (Aicher et al., 2007).
However, further studies are needed to determine the exact
source of those new endothelial cells that promote tumor growth
following high-dose radiotherapy.
Our results also suggest that BM-derived cells expressing
MMP-9 are sufficient but not essential for tumor vasculogenesis.
This is evident from the similar tumor growth in preirradiated
tissues ofWTmice +MMP-9KOBMcompared toWTmice +WTCancer Cell 13, 193–205, March 2008 ª2008 Elsevier Inc. 201
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still proficient in MMP-9, such as fibroblasts and smooth muscle
cells, can compensate for the deficiency of MMP-9 from BM
cells. MMP-9 in fibroblasts has been shown to promote mito-
genic induction of breast cancer cells by enhancing endothelial
cell survival and function in an in vitro coculture model (Shekhar
et al., 2001). This supports our observation that other sources of
MMP-9 could also play a role in promoting tumor growth and
angiogenesis. It also strengthens the rationale that MMP-9 is an
important target for adjunct therapy to radiotherapy.
Clinical trials with MMP inhibitors have been uniformly disap-
pointing. Although MMP-9 expression has been shown to corre-
late with tumor response in patients (Unsal et al., 2007), MMP
inhibitors when given alone or in combination with cytotoxic
agents showed no gain in clinical efficacy (Coussens et al.,
2002). However, none of these trials have been performed in
conjunction with radiotherapy, a therapy that can selectively in-
hibit local angiogenesis and make tumor growth dependent on
vasculogenesis. Even though currently available MMP-9 inhibi-
tors lack specificity for MMP-9 by also inhibiting the closely
related MMP-2, a recent preclinical study showed that the
MMP-2 and MMP-9 inhibitor Metastat significantly potentiated
the antitumor efficacy of irradiation (Kaliski et al., 2005), support-
ing the rationale of combining MMP inhibitors with radiotherapy.
We believe that our data point the way to further studies of
MMP-9 inhibitors with radiation.
EXPERIMENTAL PROCEDURES
Mice
All animal procedures were approved by Stanford’s Administrative Panel on
Laboratory Animal Care (APLAC). All mice except C3H [FVB/N-TgN(TIE2-
lacZ)182Sato; B6.Cg-Tg(TIE2GFP)287Sato/1J; B6;129S-Gt(ROSA)26Sor/J;
FVB-Tg(ITGAM-DTR/EGFP)34Lan/J; FVB.Cg-Tg(GFPU)5Nagy/J; FVB.Cg-
Mmp9tm1Tvu/J; FVB/NJ; and C57Bl/6J] were purchased from the Jackson
laboratory (Bar Harbor,ME). C3Hmicewere obtained from the breeding facility
at Stanford University’s Research Animal Facility. Mice were maintained in
a germ-free environment and had access to food and water available ad
libitum.
Bone Marrow Transplantation
Six- to twelve-week-old mice were used as BM recipients and donors. BM
cells from the donors were harvested from both femurs and tibias by flushing
the bone cavity with Hank’s balanced salt solution (Invitrogen, Carlsbad, CA)
using 25 gauge needles (BD, Franklin Lakes, NJ). The recipient mice were
lethally irradiated 24 hr prior to the BM transplantation. The IR doses used
were 9 Gy for FVB, MMP-9 KO, and C3H mice, and 9.5 Gy for C57Bl/6
mice. The lethally irradiated mice received >23 106 BM cell suspensions intra-
venously and were allowed to recover for a minimum of 4 weeks.
Cell Lines
The MT1A2 mouse mammary carcinoma cell line was obtained from Dr. Frank
Graham (McMaster University, Canada), the TG1-1 mouse mammary
carcinoma cell line was from Dr. Rakish Jain (Harvard University, MA), the
6780 lymphoma cell line was from Dr. Dean Felsher (Stanford University,
CA), and the B16F1melanoma cell line was from Dr. Garth Nicolson (UC Irvine,
CA). The LLC cell line was purchased from the American Tissue Culture Collec-
tion (Manassas, VA). MT1A2, TG1-1, RIF, B16F1, and LLC cells were
maintained in Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad,
CA) supplemented with 10% fetal bovine serum (FBS; Mediatech, Inc.,
Herndon, VA), and penicillin-streptomycin (1%). 6780 cells were grown in
RPMI (Invitrogen) supplemented with 10% FBS, and penicillin-streptomycin
(1%). RIF cells were constantly passaged in vitro-in vivo by implanting in
syngeneic female C3Hmice as described previously (Twentyman et al., 1980).202 Cancer Cell 13, 193–205, March 2008 ª2008 Elsevier Inc.Tumor Implantation, Irradiation, Measurement, and Perfusion
The MT1A2 and TG1-1 cells were inoculated at 1.5 3 106 cells/mouse, 6780
cells at 5 3 106 cells/mouse, and RIF, B16F1, or LLC cells at 5 3 105 cells/
mouse intradermally on the back of the mouse approximately 1 cm proximal
to the base of the tail. Unanesthetized mice were placed in lead jigs through
which the tumor implantation site or established tumors (at approximately
200 mm3 in volume) were protruded for irradiation to an area of approximately
2 cm diameter. Irradiation was performed with a Phillips X-ray unit operated at
200 kVp with the dose rate of 1.21 Gy/min (20 mA˚ with added filtration of
0.5 mm copper, the distance from X-ray source to the target of 31 cm, and
a half value layer of 1.3 mm copper). For the tumors grown in the preirradiated
site, the tumors were implanted 5 days after irradiation. Tumor volume (V) was
calculated using the formula for a spheroid: V =p/63 (width)23 (length). When
tumor volumes reached approximately 200mm3 for control tumors and slightly
more than 200 mm3 for irradiated tumors and tumors grown in the irradiated
bed, cardiac perfusion was performed in asphyxiated tumor-bearing mice
with 4% paraformaldehyde in phosphate-buffered saline (PBS; Invitrogen).
Tumors were removed, embedded in optimal cutting temperature (OCT)
compound (Sakura Finetek, Torrance, CA), and frozen in80C until cryosec-
tioning and immunostaining.
Immunostaining
Primary antibodies for immunofluorescent staining were a rat monoclonal
CD31/PECAM-1 (MEC13.3; BD PharMingen, San Diego, CA), a rabbit
polyclonal GFP antibody (Invitrogen, Eugene, OR), a rabbit polyclonal
MMP-9 (Abcam, Cambridge, MA), a biotinylated CD11b/macrophage-associ-
ated antigen-1a (M1/70; BD PharMingen), a biotinylated CD11c (HL3; BD
PharMingen), and a biotinylated Gr-1/Ly-6C (RB6-8C5; BD PharMingen).
Primary antibodies were detected by using secondary antibodies of anti-rat
Alexa Fluor 594 (Invitrogen), anti-rabbit Alexa Fluor 488 (Invitrogen), anti-rabbit
Alexa Fluor 647 (Invitrogen), or streptavidin Alexa Fluor 555 (Invitrogen). FITC-
conjugated anti-mouse a-smooth muscle actin (a-SMA) antibody (Sigma, St.
Louis, MO) was used to detect pericytes, and Phycoerythrin (PE)-conjugated
antibodies for CD4 (StemCell Technologies, Vancouver, BC, Canada),
CD8a/Ly-2 (53-6.7; BD PharMingen), and CD49b (StemCell Technologies)
were used to detect CD4, CD8a T cells, and NK cells, respectively. Frozen
sections of tumors (8 mm) were dried in air, hydrated with PBS, blocked with
5% goat serum in PBS (containing 0.03% Triton X-100) for 30 min, and incu-
bated with primary antibodies for 2 hr at room temperature (RT). Sections
were washed three times in PBS, followed by secondary antibody for 1 hr at
RT. After washing in PBS, sections were mounted with anti-fade reagent
with 40,6-diamidino-2-phenylindole (DAPI) (Invitrogen) and viewed with a
Leica DMRA2 microscope (Wetzlar, Germany) using PLAN 203/0.40 and
403/0.65 objective lenses with HC PLAN s 103/22 eyepieces. Images were
acquired with a Hamamatsu ORCA-ER camera and Improvision OpenLab
software.
Histological Assessment
MMP-9-positive area in the tumorswas determined by the point-countmethod
(Gray, 1996). Briefly, the proportions were calculated as the number of points
directly over MMP-9-positive staining divided by the total number of points
examined using a six-point grid in a 153 eyepieces at a 103 objective.
Quantitative analysis for CD11b- and MMP-9-positive cells was done by
counting the number of cells in the photographed fields where the most
CD11b were observed in nonnecrotic regions using a 403 objective with
103 eyepieces of the DMRA2 fluorescent microscope. X-gal-positive cells
were counted in five random fields per tumor with a 203 objective and 103
eyepieces of the DMLB microscope. Quantification was made on three to
five independent specimens per tumor, four to five animals per group.
Drug Treatment
ZA (Zometa; Novartis Pharma AG) was dissolved in sterile water and stored
long term at 80C and at 4C for short-term storage as reported previously
(Giraudo et al., 2004). Mice were treated every day with ZA or water from the
first day of the local irradiation at the lower back. The animals were monitored
during the treatment for their bodyweight to assess side effects and did not
show any significant loss in weight (less than 10% of bodyweight).
Cancer Cell
MMP-9-Expressing CD11b Cells in Irradiated TumorsDT (List biological laboratories Inc., CA) was prepared in sterile water
containing 1% of bovine serum albumin (BSA, Sigma). Carrageenan (Sigma)
was dissolved in saline at 10 mg/ml. Mice were treated with DT or vehicle
(1% BSA in water) once in 2 days or carrageenan once per week by intraper-
itoneal injections from the first day of the local irradiation. The treated animals
received water containing antibiotics (neomycin and polymyxin B) throughout
the study.
Statistical Analysis
Statistical comparisons of data sets were performed by a two-tailed Student’s
t test or one-way ANOVA with Tukey post test (V4.00 GraphPad Inc., CA). The
data were considered to be significantly different when p < 0.05.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures and
six supplemental figures and can be found with this article online at http://
www.cancercell.org/cgi/content/full/13/3/193/DC1/.
ACKNOWLEDGMENTS
We would like to thank Dr. Frank Graham (McMaster University, Canada) for
providing the MT1A2 mouse mammary carcinoma cell line, Dr. Rakish Jain
(Harvard University) for the TG1-1 mouse mammary carcinoma cell line, Dr.
Dean Felsher (Stanford University) for the 6780 lymphoma cell line, Dr. Mary
Jo Dorie for culturing RIF cells, Mr. Doug Menke for intravenous injection of
BM cells, and Ms. Pauline Chu for frozen sections and H&E staining. Support
was provided by the Stanford University Ludwig Translational Program in
Cancer Research, a Translational Cancer Research Award from the Stanford
Comprehensive Cancer Center, and the National Institutes of Health grant
RO1 CA-118202.
Received: May 4, 2007
Revised: October 16, 2007
Accepted: November 28, 2007
Published: March 10, 2008
REFERENCES
Aicher, A., Rentsch, M., Sasaki, K., Ellwart, J.W., Fandrich, F., Siebert, R.,
Cooke, J.P., Dimmeler, S., and Heeschen, C. (2007). Nonbone marrow-
derived circulating progenitor cells contribute to postnatal neovascularization
following tissue ischemia. Circ. Res. 100, 581–589.
Allavena, P., Signorelli, M., Chieppa, M., Erba, E., Bianchi, G., Marchesi, F.,
Olimpio, C.O., Bonardi, C., Garbi, A., Lissoni, A., et al. (2005). Anti-inflamma-
tory properties of the novel antitumor agent yondelis (trabectedin): Inhibition
of macrophage differentiation and cytokine production. Cancer Res. 65,
2964–2971.
Baeten, C.I.M., Castermans, K., Lammering, G., Hillen, F., Wouters, B.G.,
Hillen, H.F.P., Griffioen, A.W., and Baeten, C.G.M. (2006). Effects of radiother-
apy and chemotherapy on angiogenesis and leukocyte infiltration in rectal
cancer. Int. J. Radiat. Oncol. Biol. Phys. 66, 1219–1227.
Bailey, A.S., Willenbring, H., Jiang, S., Anderson, D.A., Schroeder, D.A.,
Wong, M.H., Grompe, M., and Fleming, W.H. (2006). Myeloid lineage progen-
itors give rise to vascular endothelium. Proc. Natl. Acad. Sci. USA 103,
13156–13161.
Bergers, G., and Coussens, L.M. (2000). Extrinsic regulators of epithelial tumor
progression: Metalloproteinases. Curr. Opin. Genet. Dev. 10, 120–127.
Bergers, G., Brekken, R., McMahon, G., Vu, T.H., Itoh, T., Tamaki, K.,
Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., and Hanahan, D. (2000). Matrix
metalloproteinase-9 triggers the angiogenic switch during carcinogenesis.
Nat. Cell Biol. 2, 737–744.
Bertolini, F., Shaked, Y., Mancuso, P., and Kerbel, R.S. (2006). The multifac-
eted circulating endothelial cell in cancer: Towards marker and target identifi-
cation. Nat. Rev. Cancer 6, 835–845.Capoccia, B.J., Shepherd, R.M., and Link, D.C. (2006). G-CSF and AMD3100
mobilize monocytes into the blood that stimulate angiogenesis in vivo through
a paracrine mechanism. Blood 108, 2438–2445.
Ceradini, D.J., Kulkarni, A.R., Callaghan, M.J., Tepper, O.M., Bastidas, N.,
Kleinman, M.E., Capla, J.M., Galiano, R.D., Levine, J.P., and Gurtner, G.C.
(2004). Progenitor cell trafficking is regulated by hypoxic gradients through
HIF-induction of SDF-1. Nat. Med. 10, 858–864.
Coussens, L.M., Tinkle, C.L., Hanahan, D., and Werb, Z. (2000). MMP-9
supplied by bone marrow-derived cells contributes to skin carcinogenesis.
Cell 103, 481–490.
Coussens, L.M., Fingleton, B., and Matrisian, L.M. (2002). Matrix metallopro-
teinase inhibitors and cancer: Trials and tribulations. Science 295,
2387–2392.
De Palma, M., Venneri, M.A., Roca, C., and Naldini, L. (2003). Targeting
exogenous genes to tumor angiogenesis by transplantation of genetically
modified hematopoietic stem cells. Nat. Med. 9, 789–795.
Dirkx, A.E., Oude Egbrink, M.G., Wagstaff, J., and Griffioen, A.W. (2006).
Monocyte/macrophage infiltration in tumors: Modulators of angiogenesis.
J. Leukoc. Biol. 80, 1183–1196.
Ferrara, N., Gerber, H.P., and LeCouter, J. (2003). The biology of VEGF and its
receptors. Nat. Med. 9, 669–676.
Fujiyama, S., Amano, K., Uehira, K., Yoshida, M., Nishiwaki, Y., Nozawa, Y.,
Jin, D., Takai, S., Miyazaki, M., Egashira, K., et al. (2003). Bone marrow
monocyte lineage cells adhere on injured endothelium in a monocyte
chemoattractant protein-1-dependent manner and accelerate reendotheliali-
zation as endothelial progenitor cells. Circ. Res. 93, 980–989.
Galis, Z.S., and Khatri, J.J. (2002). Matrix metalloproteinases in vascular
remodeling and atherogenesis: The good, the bad, and the ugly. Circ. Res.
90, 251–262.
Gill, M., Dias, S., Hattori, K., Rivera, M.L., Hicklin, D., Witte, L., Girardi, L., Yurt,
R., Himel, H., and Rafii, S. (2001). Vascular trauma induces rapid but transient
mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ. Res. 88,
167–174.
Giraudo, E., Inoue, M., and Hanahan, D. (2004). An amino-bisphosphonate
targets MMP-9-expressing macrophages and angiogenesis to impair cervical
carcinogenesis. J. Clin. Invest. 114, 623–633.
Gothert, J.R., Gustin, S.E., van Eekelen, J.A., Schmidt, U., Hall, M.A., Jane,
S.M., Green, A.R., Gottgens, B., Izon, D.J., and Begley, C.G. (2004).
Genetically tagging endothelial cells in vivo: Bone marrow-derived cells do
not contribute to tumor endothelium. Blood 104, 1769–1777.
Gray, T. (1996). Quantitation in histopathology. In Theory and Practice of His-
tological Techniques, J.D. Bancroft andM. Gamble, eds. (NewYork: Churchill-
Livingstone), pp. 641–663.
Grunewald, M., Avraham, I., Dor, Y., Bachar-Lustig, E., Itin, A., Jung, S.,
Chimenti, S., Landsman, L., Abramovitch, R., and Keshet, E. (2006). VEGF-
induced adult neovascularization: Recruitment, retention, and role of
accessory cells. Cell 124, 175–189.
Guy, C.T., Cardiff, R.D., andMuller, W.J. (1992). Induction of mammary tumors
by expression of polyomavirus middle T oncogene: A transgenic mousemodel
for metastatic disease. Mol. Cell. Biol. 12, 954–961.
Heissig, B., Hattori, K., Dias, S., Friedrich, M., Ferris, B., Hackett, N.R., Crystal,
R.G., Besmer, P., Lyden, D., Moore, M.A., et al. (2002). Recruitment of stem
and progenitor cells from the bone marrow niche requires MMP-9 mediated
release of kit-ligand. Cell 109, 625–637.
Heissig, B., Hattori, K., Friedrich, M., Rafii, S., and Werb, Z. (2003). Angiogen-
esis: Vascular remodeling of the extracellular matrix involves metalloprotei-
nases. Curr. Opin. Hematol. 10, 136–141.
Hiratsuka, S., Watanabe, A., Aburatani, H., and Maru, Y. (2006). Tumour-
mediated upregulation of chemoattractants and recruitment of myeloid cells
predetermines lung metastasis. Nat. Cell Biol. 8, 1369–1375.
Itasaka, S., Komaki, R., Herbst, R.S., Shibuya, K., Shintani, T., Hunter, N.R.,
Onn, A., Bucana, C.D., Milas, L., Ang, K.K., and O’Reilly, M.S. (2007). Endosta-
tin improves radioresponse and blocks tumor revascularization after radiationCancer Cell 13, 193–205, March 2008 ª2008 Elsevier Inc. 203
Cancer Cell
MMP-9-Expressing CD11b Cells in Irradiated Tumorstherapy for A431 xenografts in mice. Int. J. Radiat. Oncol. Biol. Phys. 67,
870–878.
Jodele, S., Chantrain, C.F., Blavier, L., Lutzko, C., Crooks, G.M., Shimada, H.,
Coussens, L.M., and DeClerck, Y.A. (2005). The contribution of bone marrow-
derived cells to the tumor vasculature in neuroblastoma is matrix metallopro-
teinase-9 dependent. Cancer Res. 65, 3200–3208.
Johnson, C., Sung, H.-J., Lessner, S.M., Fini, M.E., and Galis, Z.S. (2004).
Matrix metalloproteinase-9 is required for adequate angiogenic revasculariza-
tion of ischemic tissues. Potential role in capillary branching. Circ. Res. 94,
262–268.
Kaliski, A., Maggiorella, L., Cengel, K.A., Mathe, D., Rouffiac, V., Opolon, P.,
Lassau, N., Bourhis, J., and Deutsch, E. (2005). Angiogenesis and tumor
growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-
induced invasion. Mol. Cancer Ther. 4, 1717–1728.
Kim, I.H., Lemmon, M.J., and Brown, J.M. (1993). The influence of irradiation of
the tumor bed on tumor hypoxia: Measurements by radiation response,
oxygenation electrodes, and nitroimidazole binding. Radiat. Res. 135,
411–417.
Lewis, C.E., and Pollard, J.W. (2006). Distinct role of macrophages in different
tumor microenvironments. Cancer Res. 66, 605–612.
Lewis, J.S., Landers, R.J., Underwood, J.C.E., Harris, A.L., and Lewis, C.E.
(2000). Expression of vascular endothelial growth factor by macrophages is
up-regulated in poorly vascularized areas of breast carcinomas. J. Pathol.
192, 150–158.
Li, F., Sonveaux, P., Rabbani, Z.N., Liu, S., Yan, B., Huang, Q., Vujaskovic, Z.,
Dewhirst, M.W., and Li, C.Y. (2007). Regulation of HIF-1a stability through
S-nitrosylation. Mol. Cell 26, 63–74.
Liang, B.C., Thornton, A.F., Jr., Sandler, H.M., and Greenberg, H.S. (1991).
Malignant astrocytomas: Focal tumor recurrence after focal external beam
radiation therapy. J. Neurosurg. 75, 559–563.
Lin, E.Y., Nguyen, A.V., Russell, R.G., and Pollard, J.W. (2001). Colony-
stimulating factor 1 promotes progression of mammary tumors to malignancy.
J. Exp. Med. 193, 727–740.
Lin, E.Y., Li, J.F., Gnatovskiy, L., Deng, Y., Zhu, L., Grzesik, D.A., Qian, H., Xue,
X.N., and Pollard, J.W. (2006). Macrophages regulate the angiogenic switch in
a mouse model of breast cancer. Cancer Res. 66, 11238–11246.
Luo, Y., Zhou, H., Krueger, J., Kaplan, C., Lee, S.H., Dolman, C., Markowitz,
D., Wu, W., Liu, C., Reisfeld, R.A., and Xiang, R. (2006). Targeting tumor-
associated macrophages as a novel strategy against breast cancer. J. Clin.
Invest. 116, 2132–2141.
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A.,
Heissig, B., Marks, W., Witte, L., et al. (2001). Impaired recruitment of bone
marrow-derived endothelial and hematopoietic precursor cells blocks tumor
angiogenesis and growth. Nat. Med. 7, 1194–1201.
Milas, L., Ito, H., Hunter, N., Jones, S., and Peters, L.J. (1986). Retardation of
tumor growth in mice caused by radiation-induced injury of tumor bed stroma:
Dependency on tumor type. Cancer Res. 46, 723–727.
Moeller, B.J., Cao, Y., Li, C.Y., and Dewhirst, M.W. (2004). Radiation activates
HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation,
free radicals, and stress granules. Cancer Cell 5, 429–441.
Moldovan, N.I., Goldschmidt-Clermont, P.J., Parker-Thornburg, J., Shapiro,
S.D., and Kolattukudy, P.E. (2000). Contribution of monocytes/macrophages
to compensatory neovascularization: The drilling of metalloelastase-positive
tunnels in ischemic myocardium. Circ. Res. 87, 378–384.
Petit, I., Jin, D., and Rafii, S. (2007). The SDF-1-CXCR4 signaling pathway:
A molecular hub modulating neo-angiogenesis. Trends Immunol. 28, 299–
307.
Pollard, J.W. (2004). Tumour-educated macrophages promote tumour
progression and metastasis. Nat. Rev. Cancer 4, 71–78.
Rafii, S., Lyden, D., Benezra, R., Hattori, K., and Heissig, B. (2002). Vascular
and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy?
Nat. Rev. Cancer 2, 826–835.
Rofstad, E.K., Mathiesen, B., Henriksen, K., Kindem, K., and Galappathi, K.
(2005). The tumor bed effect: Increased metastatic dissemination from204 Cancer Cell 13, 193–205, March 2008 ª2008 Elsevier Inc.hypoxia-induced up-regulation of metastasis-promoting gene products.
Cancer Res. 65, 2387–2396.
Rohde, E., Malischnik, C., Thaler, D., Maierhofer, T., Linkesch, W., Lanzer, G.,
Guelly, C., and Strunk, D. (2006). Blood monocytes mimic endothelial progen-
itor cells. Stem Cells 24, 357–367.
Ruzinova, M.B., Schoer, R.A., Gerald, W., Egan, J.E., Pandolfi, P.P.,
Rafii, S., Manova, K., Mittal, V., and Benezra, R. (2003). Effect of angio-
genesis inhibition by Id loss and the contribution of bone-marrow-
derived endothelial cells in spontaneous murine tumors. Cancer Cell 4,
277–289.
Schlaeger, T.M., Bartunkova, S., Lawitts, J.A., Teichmann, G., Risau, W.,
Deutsch, U., and Sato, T.N. (1997). Uniform vascular-endothelial-cell-specific
gene expression in both embryonic and adult transgenic mice. Proc. Natl.
Acad. Sci. USA 94, 3058–3063.
Seandel, M., Noack-Kunnmann, K., Zhu, D., Aimes, R.T., and Quigley, J.P.
(2001). Growth factor-induced angiogenesis in vivo requires specific cleavage
of fibrillar type I collagen. Blood 97, 2323–2332.
Semenza, G.L. (2003). Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3,
721–732.
Shaked, Y., Ciarrocchi, A., Franco, M., Lee, C.R., Man, S., Cheung, A.M.,
Hicklin, D.J., Chaplin, D., Foster, F.S., Benezra, R., and Kerbel, R.S. (2006).
Therapy-induced acute recruitment of circulating endothelial progenitor cells
to tumors. Science 313, 1785–1787.
Shekhar, M.P.V., Werdell, J., Santner, S.J., Pauley, R.J., and Tait, L. (2001).
Breast stroma plays a dominant regulatory role in breast epithelial growth
and differentiation: Implications for tumor development and progression.
Cancer Res. 61, 1320–1326.
Shojaei, F., Wu, X., Malik, A.K., Zhong, C., Baldwin, M.E., Schanz, S., Fuh, G.,
Gerber, H.-P., and Ferrara, N. (2007). Tumor refractoriness to anti-VEGF
treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 8,
911–920.
Sica, A., Schioppa, T., Mantovani, A., and Allavena, P. (2006). Tumour-associ-
ated macrophages are a distinct M2 polarised population promoting tumour
progression: Potential targets of anti-cancer therapy. Eur. J. Cancer 42,
717–727.
Stoneman, V., Braganza, D., Figg, N., Mercerm, J., Lang, R., Goddard, M., and
Bennett, M. (2007). Monocyte/macrophage suppression in CD11b diphtheria
toxin receptor transgenic mice differentially affects atherogenesis and
established plaques. Circ. Res. 100, 884–893.
Takahashi, T., Kalka, C., Masuda, H., Chen, D., Silver, M., Kearney, M.,
Magner, M., Isner, J.M., and Asahara, T. (1999). Ischemia- and cytokine-
induced mobilization of bone marrow-derived endothelial progenitor cells for
neovascularization. Nat. Med. 5, 434–438.
Teicher, B.A., Dupuis, N.P., Robinson, M.F., Kusumoto, T., Liu, M., and
Menon, K. (1994). Reduced oxygenation in a rat mammary carcinoma
post-radiation and reoxygenation with a perflubron emulsion/carbogen
breathing. In Vivo 8, 125–131.
Tsai, J., Makonnen, S., Feldman, M., Sehgal, C.M., Maity, A., and Lee, W.M.
(2005). Ionizing radiation inhibits tumor neovascularization by inducing ineffec-
tive angiogenesis. Cancer Biol. Ther. 4, 1395–1400.
Tsai, C.S., Chen, F.H., Wang, C.C., Huang, H.L., Jung, S.M., Wu, C.J., Lee,
C.C., McBride, W.H., Chiang, C.S., and Hong, J.H. (2007). Macrophages
from irradiated tumors express higher levels of iNOS, arginase-I and
COX-2, and promote tumor growth. Int. J. Radiat. Oncol. Biol. Phys. 68,
499–507.
Twentyman, P.R., Brown, J.M., Gray, J.W., Franko, A.J., Scoles, M.A., and
Kallman, R.F. (1980). A new mouse tumor model system (RIF-1) for compari-
son of end-point studies. J. Natl. Cancer Inst. 64, 595–604.
Udagawa, T., Birsner, A.E., Wood, M., and D’Amato, R.J. (2007). Chronic
suppression of angiogenesis following radiation exposure is independent of
hematopoietic reconstitution. Cancer Res. 67, 2040–2045.
Unsal, D., Uner, A., Akyurek, N., Erpolat, P., Dursun, A., and Pak, Y. (2007).
Matrix metalloproteinase-9 expression correlated with tumor response in
Cancer Cell
MMP-9-Expressing CD11b Cells in Irradiated Tumorspatients with locally advanced rectal cancer undergoing preoperative
chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 67, 196–203.
Yang, L., DeBusk, L.M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y.,
Matrisian, L.M., Carbone, D.P., and Lin, C. (2004). Expansion of myeloid
immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes
tumor angiogenesis. Cancer Cell 6, 409–421.
Yu, Q., and Stamenkovic, I. (2000). Cell surface-localized matrix metalloprotei-
nase-9 proteolytically activates TGF-beta and promotes tumor invasion and
angiogenesis. Genes Dev. 14, 163–176.
Zeisberger, S.M., Odermatt, B., Marty, C., Zehnder-Fjallman, A.H., Ballmer-
Hofer, K., and Schwendener, R.A. (2006). Clodronate-liposome-mediated
depletion of tumour-associated macrophages: A new and highly effective
antiangiogenic therapy approach. Br. J. Cancer 95, 272–281.Cancer Cell 13, 193–205, March 2008 ª2008 Elsevier Inc. 205
